Market Overview

Mauna Kea Technologies Announces Strong Presence of Cellvizio Platform at Major Medical Meetings Focused on Gastroenterology

Share:

PARIS, May 19,2016 /PRNewswire/ --

Cellvizio Highlighted in Physician Presentations and Company Activities at Digestive Disease Week Meeting and 91st Congress of the Japan Gastroenterological Endoscopy Society

Mauna Kea Technologies (Euronext: MKEA, OTCQX: MKEAY) inventor of Cellvizio®, the multidisciplinary confocal laser endomicroscopy platform, today announced that its Cellvizio platform is being highlighted at two major medical meeting focused on gastroenterology during the month of May. The first meeting highlighting Cellvizio is Digestive Disease Week (DDW) 2016, which is being held May 21-24, 2016 in San Diego, CA. DDW is the world's largest gathering of physicians and researchers in the fields of gastroenterology, hepatology, endoscopy, and gastrointestinal surgery.

Cellvizio will be featured in 28 poster presentations and 11 oral presentations by leading physicians during the DDW meeting, a strong progression with respect to last year. In addition, at its booth (#1218), Mauna Kea will be highlighting the use of Cellvizio confocal laser endomicroscopy (CLE) in the surveillance and treatment of Barrett's Esophagus, which is a primary risk factor for developing esophageal cancer, and in the characterization of pancreatic lesions and biliary strictures.

Sacha Loiseau, Ph.D., Co-Founder and CEO of Mauna Kea Technologies, declared, "This year's DDW meeting promises to be a significant opportunity to highlight the Cellvizio platform to leading gastroenterologists from around the world, with a high number of presentations in key therapeutic areas. The use of our needle-based Cellvizio platform for the characterization of pancreatic lesions is rapidly becoming a method of choice for interventional endoscopists and we look forward to the communications around our CONTACT II 200-patient study in the following months."

The second meeting highlighting Cellvizio is the 91st Congress of the Japan Gastroenterological Endoscopy Society (JGES), which was held May 12-14, 2016 in Tokyo, Japan. The goals of the JGES are to promote fundamental and clinical research in the field of gastroenterological endoscopy and to contribute to improvements in human healthcare in Japan and worldwide through academic research. At the meeting, Cellvizio was featured in 10 physician presentations and during a dedicated luncheon seminar with more than 300 attendees.

About Mauna Kea Technologies 
Mauna Kea Technologies is a global medical device company focused on eliminating uncertainties related to the diagnosis and treatment of cancer thanks to real time in vivo microscopic visualization. The Company's flagship product, Cellvizio, has received clearance to sell a wide range of applications in more than 40 countries, including the United States, Europe, Japan, China, Canada, Brazil and Mexico.

For more information on Mauna Kea Technologies, visit www.maunakeatech.com


    Mauna Kea Technologies
    Benoit Jacheet
    CFO
    investors@maunakeatech.com

    United States
    Zack Kubow / Lee Roth
    The Ruth Group
    646-536-7020 / 7012
    zkubow@theruthgroup.com
    lroth@theruthgroup.com
    U.S. Media
    Christopher Hippolyte
    The Ruth Group
    646-536-7023
    chippolyte@theruthgroup.com
   France and Europe
    NewCap - Investor Relations
    Florent Alba
    +33 (0)1 44 71 94 94
    maunakea@newcap.fr

This is a disclosure announcement from PR Newswire.

SOURCE Mauna Kea Technologies

View Comments and Join the Discussion!